[CLS] O
to O
##rsa X
##de X
de O
point O
##es X
vent O
##ric X
##ular X
ta O
##chy X
##card X
##ia X
during O
low O
dose O
intermittent O
do B
##but X
##amine X
treatment O
in O
a O
patient O
with O
di O
##lated X
card O
##io X
##my X
##op X
##athy X
and O
con O
##ges X
##tive X
heart O
failure O
. O
[SEP] O
[CLS] O
the O
authors O
describe O
the O
case O
of O
a O
56 O
- O
year O
- O
old O
woman O
with O
chronic O
, O
severe O
heart O
failure O
secondary O
to O
di O
##lated X
card O
##io X
##my X
##op X
##athy X
and O
absence O
of O
significant O
vent O
##ric X
##ular X
a O
##rr X
##hy X
##th X
##mia X
##s X
who O
developed O
q O
##t X
pro O
##long X
##ation X
and O
to O
##rsa X
##de X
de O
point O
##es X
vent O
##ric X
##ular X
ta O
##chy X
##card X
##ia X
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2 O
. O
5 O
m O
##c X
##g X
/ O
kg O
per O
min O
) O
do B
##but X
##amine X
. O
[SEP] O
[CLS] O
this O
report O
of O
to O
##rsa X
##de X
de O
point O
##es X
vent O
##ric X
##ular X
ta O
##chy X
##card X
##ia X
during O
intermittent O
do B
##but X
##amine X
supports O
the O
hypothesis O
that O
unpredictable O
fatal O
a O
##rr X
##hy X
##th X
##mia X
##s X
may O
occur O
even O
with O
low O
doses O
and O
in O
patients O
with O
no O
history O
of O
significant O
rhythm O
disturbance O
##s X
. O
[SEP] O
[CLS] O
the O
mechanisms O
of O
pro O
##ar X
##r X
##hy X
##th X
##mic X
effects O
of O
dub B
##uta X
##mine X
are O
discussed O
. O
[SEP] O
[CLS] O
positive O
skin O
tests O
in O
late O
reactions O
to O
radio O
##graphic X
contrast B
media I
. O
[SEP] O
[CLS] O
in O
the O
last O
few O
years O
delayed O
reactions O
several O
hours O
after O
the O
injection O
of O
radio O
##graphic X
and O
contrast O
materials O
( O
p O
##rc X
) O
have O
been O
described O
with O
increasing O
frequency O
. O
[SEP] O
[CLS] O
the O
authors O
report O
two O
observations O
on O
patients O
with O
delayed O
reactions O
in O
whom O
in O
##tra X
##der X
##more X
##actions X
( O
id O
##r X
) O
and O
patch O
tests O
to O
a O
series O
of O
ion O
##ic X
and O
non O
ion O
##ic X
p O
##rc X
were O
studied O
. O
[SEP] O
[CLS] O
after O
an O
##gio X
##graphy X
by O
the O
ve O
##nous X
route O
in O
patient O
n O
degree O
1 O
a O
bi O
##pha X
##si X
##c X
reaction O
with O
an O
immediate O
reaction O
( O
d O
##ys X
##p X
##nea X
, O
loss O
of O
consciousness O
) O
and O
delayed O
mac O
##ro X
- O
p O
##ap X
##ular X
r O
##ash X
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
general O
##ised X
sensation O
of O
heat O
, O
persistent O
pain O
at O
the O
site O
of O
injection O
immediately O
and O
a O
general O
##ised X
mac O
##ro X
- O
p O
##ap X
##ular X
reaction O
after O
24 O
hours O
. O
[SEP] O
[CLS] O
the O
skin O
tests O
revealed O
positive O
delayed O
reactions O
of O
24 O
hours O
and O
48 O
hours O
by O
id O
##r X
and O
patch O
tests O
to O
only O
some O
p O
##rc X
with O
common O
chains O
in O
their O
structures O
. O
[SEP] O
[CLS] O
the O
positive O
skin O
tests O
are O
in O
favour O
of O
im O
##mu X
##nological X
reactions O
and O
may O
help O
in O
diagnosis O
of O
all O
##er X
##gy X
in O
the O
patients O
. O
[SEP] O
[CLS] O
risk O
of O
trans O
##ient X
h O
##yper X
##am X
##mon X
##em X
##ic X
en O
##ce X
##pha X
##lop X
##athy X
in O
cancer O
patients O
who O
received O
continuous O
in O
##fusion X
of O
5 B
- I
flu I
##oro X
##ura X
##ci X
##l X
with O
the O
com O
##plication X
of O
de O
##hy X
##dra X
##tion X
and O
infection O
. O
[SEP] O
[CLS] O
from O
1986 O
to O
1998 O
, O
29 O
cancer O
patients O
who O
had O
32 O
episodes O
of O
trans O
##ient X
h O
##yper X
##am X
##mon X
##em X
##ic X
en O
##ce X
##pha X
##lop X
##athy X
related O
to O
continuous O
in O
##fusion X
of O
5 B
- I
flu I
##oro X
##ura X
##ci X
##l X
( O
5 B
- I
f I
##u X
) O
were O
identified O
. O
[SEP] O
[CLS] O
none O
of O
the O
patients O
had O
de O
##com X
##pen X
##sat X
##ed X
liver O
disease O
. O
[SEP] O
[CLS] O
onset O
of O
h O
##yper X
##am X
##mon X
##em X
##ic X
en O
##ce X
##pha X
##lop X
##athy X
varied O
from O
0 O
. O
5 O
to O
5 O
days O
( O
mean O
: O
2 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
days O
) O
after O
the O
initiation O
of O
ch O
##em X
##otherapy X
. O
[SEP] O
[CLS] [CLS]
plasma O
am B
##mon X
##ium X
level O
ranged O
from O
248 O
to O
238 O
##7 X
micro O
##g X
% O
( O
mean O
: O
62 O
##6 X
+ O
/ O
- O
43 O
##1 X
micro O
##g X
% O
) O
. O
[SEP] O
[CLS] O
among O
the O
32 O
episodes O
, O
26 O
( O
81 O
% O
) O
had O
various O
degrees O
of O
a O
##zo X
##tem X
##ia X
, O
18 O
( O
56 O
% O
) O
occurred O
during O
bacterial O
infections O
and O
14 O
( O
44 O
% O
) O
without O
infection O
occurred O
during O
periods O
of O
de O
##hy X
##dra X
##tion X
. O
[SEP] O
[CLS] O
higher O
plasma O
am B
##mon X
##ium X
levels O
and O
more O
rapid O
onset O
of O
h O
##yper X
##am X
##mon X
##emia X
were O
seen O
in O
18 O
patients O
with O
bacterial O
infections O
( O
p O
= O
0 O
. O
00 O
##3 X
and O
0 O
. O
000 O
##6 X
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
260 O
##0 X
or O
1800 O
mg O
/ O
m O
##2 X
) O
of O
5 B
- I
f I
##u X
( O
p O
= O
0 O
. O
000 O
##1 X
and O
< O
0 O
. O
000 O
##1 X
, O
respectively O
) O
. O
[SEP] O
[CLS] O
in O
25 O
out O
of O
32 O
episodes O
( O
78 O
% O
) O
, O
plasma O
am B
##mon X
##ium X
levels O
and O
mental O
status O
returned O
to O
normal O
within O
2 O
days O
after O
adequate O
management O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
h O
##yper X
##am X
##mon X
##em X
##ic X
en O
##ce X
##pha X
##lop X
##athy X
can O
occur O
in O
patients O
receiving O
continuous O
in O
##fusion X
of O
5 B
- I
f I
##u X
. O
[SEP] O
[CLS] [CLS]
a O
##zo X
##tem X
##ia X
, O
body O
fluid O
ins O
##uff X
##iciency X
and O
bacterial O
infections O
were O
frequently O
found O
in O
these O
patients O
. O
[SEP] O
[CLS] O
it O
is O
therefore O
important O
to O
recognize O
this O
condition O
in O
patients O
receiving O
continuous O
in O
##fusion X
of O
5 B
- I
f I
##u X
. O
[SEP] O
[CLS] O
the O
effects O
of O
q B
##uin X
##ine X
and O
4 B
- I
amino I
##py X
##rid X
##ine X
on O
conditioned O
place O
preference O
and O
changes O
in O
motor O
activity O
induced O
by O
m O
##or X
##phine X
in O
rats O
. O
[SEP] O
[CLS] O
1 O
. O
[SEP] O
[CLS] O
the O
effects O
of O
two O
un O
##sel X
##ec X
##tive X
potassium B
( O
k O
( O
+ O
) O
- O
) O
channel O
block O
##ers X
, O
q B
##uin X
##ine X
( O
12 O
. O
5 O
, O
25 O
and O
50 O
mg O
/ O
kg O
) O
and O
4 B
- I
amino I
##py X
##rid X
##ine X
( O
1 O
and O
2 O
mg O
/ O
kg O
) O
, O
on O
conditioned O
place O
preference O
and O
bi O
##pha X
##si X
##c X
changes O
in O
motor O
activity O
induced O
by O
m B
##or X
##phine X
( O
10 O
mg O
/ O
kg O
) O
were O
tested O
in O
w O
##ista X
##r X
rats O
. O
[SEP] O
[CLS] O
q B
##uin X
##ine X
is O
known O
to O
block O
voltage O
- O
, O
calcium B
- O
and O
at O
##p X
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
while O
4 B
- I
amino I
##py X
##rid X
##ine X
is O
known O
to O
block O
voltage O
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
. O
[SEP] O
[CLS] O
2 O
. O
[SEP] O
[CLS] O
in O
the O
counter O
##bal X
##ance X
##d X
method O
, O
q B
##uin X
##ine X
at O
##ten X
##uated O
m B
##or X
##phine X
- O
induced O
place O
preference O
, O
whereas O
4 B
- I
amino I
##py X
##rid X
##ine X
was O
ineffective O
. O
[SEP] O
[CLS] O
in O
the O
motor O
activity O
test O
measured O
with O
an O
anime O
##x X
- O
activity O
meter O
neither O
of O
the O
k O
( O
+ O
) O
- O
channel O
block O
##ers X
affected O
m B
##or X
##phine X
- O
induced O
h O
##y X
##po X
##act X
##ivity X
, O
but O
both O
k O
( O
+ O
) O
- O
channel O
block O
##ers X
prevented O
m B
##or X
##phine X
- O
induced O
secondary O
h O
##yper X
##act X
##ivity X
. O
[SEP] O
[CLS] O
3 O
. O
[SEP] O
[CLS] O
these O
results O
suggest O
the O
involvement O
of O
q B
##uin X
##ine X
- O
sensitive O
but O
not O
4 B
- I
amino I
##py X
##rid X
##ine X
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
in O
m B
##or X
##phine X
reward O
. O
[SEP] O
[CLS] O
it O
is O
also O
suggested O
that O
the O
blockade O
of O
k O
( O
+ O
) O
- O
channels O
sensitive O
to O
these O
block O
##ers X
is O
not O
sufficient O
to O
prevent O
m B
##or X
##phine X
- O
induced O
h O
##y X
##po X
##act X
##ivity X
whereas O
m B
##or X
##phine X
- O
induced O
h O
##yper X
##act X
##ivity X
seems O
to O
be O
connected O
to O
both O
q B
##uin X
##ine X
- O
and O
4 B
- I
amino I
##py X
##rid X
##ine X
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
. O
[SEP] O
[CLS] O
no O
##ci X
##ce X
##pt X
##in X
/ O
orphan O
##in X
f O
##q X
and O
no O
##cist X
##ati X
##n X
on O
learning O
and O
memory O
imp O
##air X
##ment X
induced O
by O
s B
##co X
##pol X
##amine X
in O
mice O
. O
[SEP] O
[CLS] O
1 O
. O
[SEP] O
[CLS] O
no O
##ci X
##ce X
##pt X
##in X
, O
also O
known O
as O
orphan O
##in X
f O
##q X
, O
is O
an O
end O
##ogen X
##ous X
l O
##igan X
##d X
for O
the O
orphan O
op O
##io X
##id X
receptor O
- O
like O
receptor O
1 O
( O
or O
##l X
##1 X
) O
and O
involves O
in O
various O
functions O
in O
the O
central O
nervous O
system O
( O
c O
##ns X
) O
. O
[SEP] O
[CLS] O
on O
the O
other O
hand O
, O
no O
##cist X
##ati X
##n X
is O
recently O
isolated O
from O
the O
same O
precursor O
as O
no B
##ci X
##ce X
##pt X
##in X
and O
blocks O
no B
##ci X
##ce X
##pt X
##in X
- O
induced O
all O
##ody X
##nia X
and O
h O
##yper X
##al X
##ges X
##ia X
. O
[SEP] O
[CLS] O
2 O
. O
[SEP] O
[CLS] O
although O
or O
##l X
##1 X
receptors O
which O
display O
a O
high O
degree O
of O
sequence O
ho O
##mology X
with O
classical O
op O
##io X
##id X
receptors O
are O
abundant O
in O
the O
hip O
##po X
##cam X
##pus X
, O
little O
is O
known O
regarding O
their O
role O
in O
learning O
and O
memory O
. O
[SEP] O
[CLS] O
3 O
. O
[SEP] O
[CLS] O
the O
present O
study O
was O
designed O
to O
investigate O
whether O
no O
##ci X
##ce X
##pt X
##in X
/ O
orphan O
##in X
f O
##q X
and O
no O
##cist X
##ati X
##n X
could O
m O
##od X
##ulate X
imp O
##air X
##ment X
of O
learning O
and O
memory O
induced O
by O
s B
##co X
##pol X
##amine X
, O
a O
m O
##us X
##car X
##ini X
##c X
ch O
##olin X
##ergic X
receptor O
antagonist O
, O
using O
spontaneous O
alter O
##nation X
of O
y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoid O
##ance X
tasks O
in O
mice O
. O
[SEP] O
[CLS] O
4 O
. O
[SEP] O
[CLS] O
while O
no O
##cist X
##ati X
##n X
( O
0 O
. O
5 O
- O
5 O
. O
0 O
nm O
##ol X
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
administered O
30 O
min O
before O
spontaneous O
alter O
##nation X
performance O
or O
the O
training O
session O
of O
the O
passive O
avoid O
##ance X
task O
, O
had O
no O
effect O
on O
spontaneous O
alter O
##nation X
or O
passive O
avoid O
##ance X
behaviour O
##s X
, O
a O
lower O
per O
cent O
alter O
##nation X
and O
shorter O
median O
step O
- O
down O
late O
##ncy X
in O
the O
retention O
test O
were O
obtained O
in O
no B
##ci X
##ce X
##pt X
##in X
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nm O
##ol X
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
- O
treated O
normal O
mice O
. O
[SEP] O
[CLS] O
5 O
. O
[SEP] O
[CLS] O
administration O
of O
no O
##cist X
##ati X
##n X
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nm O
##ol X
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
30 O
min O
before O
spontaneous O
alter O
##nation X
performance O
or O
the O
training O
session O
of O
the O
passive O
avoid O
##ance X
task O
, O
at O
##ten X
##uated X
the O
s B
##co X
##pol X
##amine X
- O
induced O
imp O
##air X
##ment X
of O
spontaneous O
alter O
##nation X
and O
passive O
avoid O
##ance X
behaviour O
##s X
. O
[SEP] O
[CLS] O
6 O
. O
[SEP] O
[CLS] O
these O
results O
indicated O
that O
no O
##cist X
##ati X
##n X
, O
a O
new O
biological O
##ly X
active O
p O
##eptide X
, O
am O
##eli X
##ora X
##tes X
imp O
##air X
##ments X
of O
spontaneous O
alter O
##nation X
and O
passive O
avoid O
##ance X
induced O
by O
s B
##co X
##pol X
##amine X
, O
and O
suggested O
that O
these O
p O
##eptide X
##s X
play O
opposite O
roles O
in O
learning O
and O
memory O
. O
[SEP] O
[CLS] O
me O
##lo X
##xi X
##cam X
- O
induced O
liver O
toxicity O
. O
[SEP] O
[CLS] [PAD]
we O
report O
the O
case O
of O
a O
female O
patient O
with O
r O
##he X
##uma X
##to X
##id X
art O
##hr X
##itis X
who O
developed O
acute O
c O
##yt X
##oly X
##tic X
he O
##pa X
##titis X
due O
to O
me B
##lo X
##xi X
##cam X
. O
[SEP] O
[CLS] O
recently O
introduced O
in O
be B
##l X
##gi X
##um X
, O
me B
##lo X
##xi X
##cam X
is O
the O
first O
non O
##ster X
##oid X
##al X
anti O
##in X
##f X
##lam X
##mat X
##ory X
drug O
with O
selective O
action O
on O
the O
in O
##du X
##cible X
form O
of O
c O
##y X
##c X
##lo X
##ox X
##y X
##gen X
##ase X
2 O
. O
[SEP] O
[CLS] O
the O
acute O
c O
##yt X
##oly X
##tic X
he O
##pa X
##titis X
occurred O
rapidly O
after O
me B
##lo X
##xi X
##cam X
administration O
and O
was O
associated O
with O
the O
development O
of O
anti O
##nu X
##cle X
##ar X
antibodies O
suggesting O
a O
h O
##yper X
##sen X
##si X
##ti X
##vity X
mechanism O
. O
[SEP] O
[CLS] O
this O
first O
case O
of O
me B
##lo X
##xi X
##cam X
related O
liver O
toxicity O
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
he O
##pa X
##tic X
damage O
. O
[SEP] O
[CLS] O
induction O
of O
a O
##pop X
##tosis X
by O
re B
##mo X
##xi X
##p X
##ride X
meta O
##bol X
##ites X
in O
h O
##l X
##60 X
and O
c O
##d X
##34 X
+ O
/ O
c O
##d X
##19 X
- O
human O
bone O
ma O
##rrow X
pro O
##gen X
##itor X
cells O
: O
potential O
relevance O
to O
re B
##mo X
##xi X
##p X
##ride X
- O
induced O
a O
##p X
##lastic X
an O
##emia X
. O
[SEP] O
[CLS] O
the O
anti O
##psy X
##cho X
##tic X
agent O
, O
re B
##mo X
##xi X
##p X
##ride X
[ O
( O
s O
) O
- O
( O
- O
) O
- O
3 B
- I
br I
##omo X
- I
n I
- I
[ I
( I
1 I
- I
et I
##hyl X
- I
2 I
- I
p I
##yr X
##rol X
##id X
##in X
##yl X
) I
met I
##hyl X
] I
- I
2 I
, I
6 I
- I
dim I
##eth X
##ox X
##y X
##ben X
##z X
amid I
##e X
] O
has O
been O
associated O
with O
acquired O
a O
##p X
##lastic X
an O
##emia X
. O
[SEP] O
[CLS] O
we O
have O
examined O
the O
ability O
of O
re B
##mo X
##xi X
##p X
##ride X
, O
three O
p B
##yr X
##rol X
##id X
##ine X
ring O
meta O
##bol X
##ites X
and O
five O
a O
##romatic X
ring O
meta O
##bol X
##ites X
of O
the O
parent O
compound O
to O
induce O
a O
##pop X
##tosis X
in O
h O
##l X
##60 X
cells O
and O
human O
bone O
ma O
##rrow X
pro O
##gen X
##itor X
( O
h O
##b X
##mp X
) O
cells O
. O
[SEP] O
[CLS] [CLS]
cells O
were O
treated O
for O
0 O
- O
24 O
h O
with O
each O
compound O
( O
0 O
- O
200 O
micro O
##m X
) O
. O
[SEP] O
[CLS] O
a O
##pop X
##tosis X
was O
assessed O
by O
flu O
##ores X
##cence X
micro O
##sco X
##py X
in O
ho B
##ech X
##st X
333 I
##42 X
- O
and O
prop B
##id X
##ium X
i I
##od X
##ide X
stained O
cell O
samples O
. O
[SEP] O
[CLS] O
results O
were O
confirmed O
by O
determination O
of O
inter O
##nu X
##cle X
##oso X
##mal X
d O
##na X
fragment O
##ation X
using O
gel O
electro O
##ph X
##ores X
##is X
for O
h O
##l X
##60 X
cell O
samples O
and O
terminal O
de O
##ox X
##yn X
##uc X
##leo X
##ti X
##dy X
##l X
transfer O
##ase X
ass O
##ay X
in O
h O
##b X
##mp X
cells O
. O
[SEP] O
[CLS] O
the O
cat B
##ech X
##ol X
and O
h B
##ydro X
##quin X
##one X
meta O
##bol X
##ites X
, O
n O
##c X
##q X
##43 X
##6 X
and O
n O
##c X
##q X
##34 X
##4 X
, O
induced O
a O
##pop X
##tosis X
in O
h O
##l X
##60 X
and O
h O
##b X
##mp X
cells O
in O
a O
time O
- O
and O
concentration O
dependent O
manner O
, O
while O
the O
p B
##hen X
##ols X
, O
n O
##c X
##r X
##18 X
##1 X
, O
fl O
##a X
##8 X
##7 X
##3 X
, O
and O
fl B
##a X
##7 X
##9 X
##7 X
, O
and O
the O
derivatives O
formed O
by O
oxidation O
of O
the O
p B
##yr X
##rol X
##id X
##ine X
ring O
, O
fl B
##a X
##8 X
##38 X
, O
n O
##c X
##m X
##00 X
##1 X
, O
and O
n O
##c X
##l X
##11 X
##8 X
, O
had O
no O
effect O
. O
[SEP] O
[CLS] O
no O
ne O
##c X
##rosis X
was O
observed O
in O
cells O
treated O
with O
n B
##c X
##q X
##43 X
##6 X
but O
n B
##c X
##q X
##34 X
##4 X
had O
a O
bi O
##pha X
##si X
##c X
effect O
in O
both O
cell O
types O
, O
in O
##ducing X
a O
##pop X
##tosis X
at O
lower O
concentrations O
and O
ne O
##c X
##rosis X
at O
higher O
concentrations O
. O
[SEP] O
[CLS] O
these O
data O
show O
that O
the O
cat B
##ech X
##ol X
and O
h B
##ydro X
##quin X
##one X
meta O
##bol X
##ites X
of O
re B
##mo X
##xi X
##p X
##ride X
have O
direct O
toxic O
effects O
in O
h O
##l X
##60 X
and O
h O
##b X
##mp X
cells O
, O
leading O
to O
a O
##pop X
##tosis X
, O
while O
the O
p B
##hen X
##ol X
meta O
##bol X
##ites X
were O
inactive O
. O
[SEP] O
[CLS] O
similarly O
, O
ben B
##zen X
##e X
- O
derived O
cat B
##ech X
##ol X
and O
h B
##ydro X
##quin X
##one X
, O
but O
not O
p B
##hen X
##ol X
, O
induce O
a O
##pop X
##tosis X
in O
h O
##b X
##mp X
cells O
[ O
m O
##oran X
et O
al O
. O
, O
m O
##ol X
. O
p O
##har X
##ma X
##co X
##l X
. O
, O
50 O
( O
1996 O
) O
610 O
- O
61 O
##5 X
] O
. O
[SEP] O
[CLS] O
we O
propose O
that O
re B
##mo X
##xi X
##p X
##ride X
and O
ben B
##zen X
##e X
may O
induce O
a O
##p X
##lastic X
an O
##emia X
via O
production O
of O
similar O
reactive O
meta O
##bol X
##ites X
and O
that O
the O
ability O
of O
n O
##c X
##q X
##43 X
##6 X
and O
n O
##c X
##q X
##34 X
##4 X
to O
induce O
a O
##pop X
##tosis X
in O
h O
##b X
##mp X
cells O
may O
contribute O
to O
the O
mechanism O
underlying O
acquired O
a O
##p X
##lastic X
an O
##emia X
that O
has O
been O
associated O
with O
re B
##mo X
##xi X
##p X
##ride X
. O
[SEP] O
[CLS] O
synthesis O
and O
preliminary O
p O
##har X
##ma X
##cological X
investigations O
of O
1 B
- I
( I
1 I
, I
2 I
- I
di I
##hy X
##dr X
##o X
- I
2 I
- I
ace I
##nap X
##ht X
##hyl X
##en X
##yl X
) I
pipe I
##raz X
##ine X
derivatives O
as O
potential O
at O
##y X
##pical X
anti O
##psy X
##cho X
##tic X
agents O
in O
mice O
. O
[SEP] O
[CLS] O
in O
research O
towards O
the O
development O
of O
new O
at O
##y X
##pical X
anti O
##psy X
##cho X
##tic X
agents O
, O
one O
strategy O
is O
that O
the O
do O
##pa X
##mine X
##rg X
##ic X
system O
can O
be O
m O
##od X
##ulated X
through O
manipulation O
of O
the O
se O
##rot X
##one X
##rg X
##ic X
system O
. O
[SEP] O
[CLS] O
the O
synthesis O
and O
preliminary O
p O
##har X
##ma X
##cological X
evaluation O
of O
a O
series O
of O
potential O
at O
##y X
##pical X
anti O
##psy X
##cho X
##tic X
agents O
based O
on O
the O
structure O
of O
1 B
- I
( I
1 I
, I
2 I
- I
di I
##hy X
##dr X
##o X
- I
2 I
- I
ace I
##nap X
##ht X
##hyl X
##en X
##yl X
) I
pipe I
##raz X
##ine X
( O
7 O
) O
is O
described O
. O
[SEP] O
[CLS] O
compound O
7 O
##e X
, O
5 B
- I
{ I
2 I
- I
[ I
4 I
- I
( I
1 I
, I
2 I
- I
di I
##hy X
##dr X
##o X
- I
2 I
- I
ace I
##nap X
##ht X
##hyl X
##en X
##yl X
) I
pipe I
##raz X
##in X
##yl X
] I
et I
##hyl X
} I
- I
2 I
, I
3 I
- I
di I
##hy X
d I
##ro X
- I
1 I
##h X
- I
in O
##do X
##l X
- I
2 I
- I
one I
, O
from O
this O
series O
showed O
significant O
a O
##ffin X
##ities X
at O
the O
5 O
- O
h O
##t X
##1 X
##a X
and O
5 O
- O
h O
##t X
##2 X
##a X
receptors O
and O
moderate O
affinity O
at O
the O
d O
##2 X
receptor O
. O
[SEP] O
[CLS] O
7 O
##e X
exhibits O
a O
high O
reversal O
of O
cat O
##ale X
##psy X
induced O
by O
ha B
##lop X
##eri X
##do X
##l X
indicating O
its O
at O
##y X
##pical X
anti O
##psy X
##cho X
##tic X
nature O
. O
[SEP] O
[CLS] O
sub O
- O
chronic O
in O
##hibition X
of O
ni B
##tric X
- I
oxide I
synthesis O
m O
##od X
##ifies X
ha B
##lop X
##eri X
##do X
##l X
- O
induced O
cat O
##ale X
##psy X
and O
the O
number O
of O
na O
##d X
##ph X
- O
di O
##aph X
##ora X
##se X
neurons O
in O
mice O
. O
[SEP] O
[CLS] O
rational O
##e X
: O
ng B
- I
ni I
##tro X
- I
l I
- I
a O
##rg X
##ini X
##ne X
( O
l B
- I
no I
##ar X
##g X
) O
, O
an O
inhibitor O
of O
ni B
##tric X
- I
oxide I
s O
##ynth X
##ase X
( O
no O
##s X
) O
, O
induce O
##s X
cat O
##ale X
##psy X
in O
mice O
. O
[SEP] O
[CLS] O
this O
effect O
undergo O
##es O
rapid O
tolerance O
, O
showing O
a O
significant O
decrease O
after O
2 O
days O
of O
sub O
- O
chronic O
l B
- I
no I
##ar X
##g X
treatment O
. O
[SEP] O
[CLS] O
ni B
##tric X
oxide I
( O
no O
) O
has O
been O
shown O
to O
influence O
do O
##pa X
##mine X
##rg X
##ic X
ne O
##uro X
##tra X
##ns X
##mission X
in O
the O
s O
##tri X
##at X
##um X
. O
[SEP] O
[CLS] O
ne O
##uro X
##le X
##ptic X
drugs O
such O
as O
ha B
##lop X
##eri X
##do X
##l X
, O
which O
block O
do B
##pa X
##mine X
receptors O
, O
also O
cause O
cat O
##ale X
##psy X
in O
rode O
##nts X
. O
[SEP] O
[CLS] O
objectives O
: O
to O
investigate O
the O
effects O
of O
sub O
##ch X
##ronic X
l B
- I
no I
##ar X
##g X
treatment O
in O
ha B
##lop X
##eri X
##do X
##l X
- O
induced O
cat O
##ale X
##psy X
and O
the O
number O
of O
no O
##s X
neurons O
in O
areas O
related O
to O
motor O
control O
. O
[SEP] O
[CLS] O
methods O
: O
male O
al O
##bino X
s O
##wi X
##ss X
mice O
were O
treated O
sub O
- O
chronic O
##ally X
( O
twice O
a O
day O
for O
4 O
days O
) O
with O
l B
- I
no O
##ar X
##g X
( O
40 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
or O
ha B
##lop X
##eri X
##do X
##l X
( O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O
[SEP] O
[CLS] O
cat O
##ale X
##psy X
was O
evaluated O
at O
the O
beginning O
and O
the O
end O
of O
the O
treatments O
. O
[SEP] O
[CLS] O
reduced O
ni B
##cot X
##ina X
##mi X
##de X
ad I
##eni X
##ne X
din I
##uc X
##leo X
##tide X
phosphate I
- O
di O
##aph X
##ora X
##se X
( O
na O
##d X
##ph X
- O
d O
) O
his O
##to X
##chemistry X
was O
also O
employed O
to O
visual O
##ize X
no O
##s X
as O
an O
index O
of O
enzyme O
expression O
in O
mice O
brain O
regions O
related O
to O
motor O
control O
. O
[SEP] O
[CLS] O
results O
: O
l B
- I
no O
##ar X
##g X
sub O
- O
chronic O
administration O
produced O
tolerance O
of O
l B
- I
no I
##ar X
##g X
and O
of O
ha B
##lop X
##eri X
##do X
##l X
- O
induced O
cat O
##ale X
##psy X
. O
[SEP] O
[CLS] O
it O
also O
induced O
an O
increase O
in O
the O
number O
of O
na O
##d X
##ph X
- O
d O
- O
positive O
cells O
in O
the O
dorsal O
part O
of O
the O
ca O
##uda X
##te X
and O
a O
##cc X
##um X
##ben X
##s X
nuclei O
compared O
with O
ha B
##lop X
##eri X
##do X
##l X
and O
in O
the O
p O
##ed X
##un X
##cu X
##lop X
##ont X
##ine X
te O
##gment X
##al X
nucleus O
compared O
with O
sa O
##line X
. O
[SEP] O
[CLS] O
in O
contrast O
, O
there O
was O
a O
decrease O
in O
na O
##d X
##ph X
- O
d O
ne O
##uron X
number O
in O
the O
sub O
##stant X
##ia X
ni O
##gra X
, O
par O
##s X
compact O
##a X
in O
both O
ha B
##lop X
##eri X
##do X
##l X
- O
treated O
and O
l B
- I
no I
##ar X
##g X
- O
treated O
animals O
. O
[SEP] O
[CLS] O
conclusions O
: O
the O
results O
give O
further O
support O
to O
the O
hypothesis O
that O
no O
plays O
a O
role O
in O
motor O
behavior O
control O
and O
suggest O
that O
it O
may O
take O
part O
in O
the O
s O
##yna X
##ptic X
changes O
produced O
by O
anti O
##psy X
##cho X
##tic X
treatment O
. O
[SEP] O
[CLS] O
prolonged O
left O
vent O
##ric X
##ular X
d O
##ys X
##function X
occurs O
in O
patients O
with O
co O
##rona X
##ry X
artery O
disease O
after O
both O
do B
##but X
##amine X
and O
exercise O
induced O
my O
##oc X
##ard X
##ial X
is O
##cha X
##emia X
. O
[SEP] O
[CLS] O
objective O
: O
to O
determine O
whether O
p O
##har X
##ma X
##cological X
stress O
leads O
to O
prolonged O
but O
re O
##versible X
left O
vent O
##ric X
##ular X
d O
##ys X
##function X
in O
patients O
with O
co O
##rona X
##ry X
artery O
disease O
, O
similar O
to O
that O
seen O
after O
exercise O
. O
[SEP] O
[CLS] O
design O
: O
a O
random O
##ised O
crossover O
study O
of O
recovery O
time O
of O
s O
##ys X
##to X
##lic X
and O
di O
##ast X
##olic X
left O
vent O
##ric X
##ular X
function O
after O
exercise O
and O
do B
##but X
##amine X
induced O
is O
##cha X
##emia X
. O
[SEP] O
[CLS] O
subjects O
: O
10 O
patients O
with O
stable O
an O
##gin X
##a X
, O
an O
##gio X
##graphical X
##ly X
proven O
co O
##rona X
##ry X
artery O
disease O
, O
and O
normal O
left O
vent O
##ric X
##ular X
function O
. O
[SEP] O
[CLS] O
interventions O
: O
t O
##read X
##mill X
exercise O
and O
do B
##but X
##amine X
stress O
were O
performed O
on O
different O
days O
. O
[SEP] O
[CLS] O
quantitative O
assessment O
of O
s O
##ys X
##to X
##lic X
and O
di O
##ast X
##olic X
left O
vent O
##ric X
##ular X
function O
was O
performed O
using O
trans O
##th X
##ora X
##ci X
##c X
echo O
##card X
##io X
##graphy X
at O
base O
##line X
and O
at O
regular O
intervals O
after O
each O
test O
. O
[SEP] O
[CLS] O
results O
: O
both O
forms O
of O
stress O
led O
to O
prolonged O
but O
re O
##versible X
s O
##ys X
##to X
##lic X
and O
di O
##ast X
##olic X
d O
##ys X
##function X
. O
[SEP] O
[CLS] O
there O
was O
no O
difference O
in O
the O
maximum O
double O
product O
( O
p O
= O
0 O
. O
53 O
) O
or O
s O
##t X
depression O
( O
p O
= O
0 O
. O
63 O
) O
with O
either O
form O
of O
stress O
. O
[SEP] O
[CLS] O
after O
exercise O
, O
e O
##jection X
fraction O
was O
reduced O
at O
15 O
and O
30 O
minutes O
compared O
with O
base O
##line X
( O
mean O
( O
se O
##m X
) O
, O
- O
5 O
. O
6 O
( O
1 O
. O
5 O
) O
% O
, O
p O
< O
0 O
. O
05 O
; O
and O
- O
6 O
. O
1 O
( O
2 O
. O
2 O
) O
% O
, O
p O
< O
0 O
. O
01 O
) O
, O
and O
at O
30 O
and O
45 O
minutes O
after O
do B
##but X
##amine X
( O
- O
10 O
. O
8 O
( O
1 O
. O
8 O
) O
% O
and O
- O
5 O
. O
5 O
( O
1 O
. O
8 O
) O
% O
, O
both O
p O
< O
0 O
. O
01 O
) O
. O
[SEP] O
[CLS] O
regional O
analysis O
showed O
a O
reduction O
in O
the O
worst O
affected O
segment O
15 O
and O
30 O
minutes O
after O
exercise O
( O
- O
27 O
. O
9 O
( O
7 O
. O
2 O
) O
% O
and O
- O
28 O
. O
6 O
( O
5 O
. O
7 O
) O
% O
, O
both O
p O
< O
0 O
. O
01 O
) O
, O
and O
at O
30 O
minutes O
after O
do B
##but X
##amine X
( O
- O
32 O
( O
5 O
. O
3 O
) O
% O
, O
p O
< O
0 O
. O
01 O
) O
. O
[SEP] O
[CLS] [CLS]
the O
is O
##ovo X
##lum X
##ic X
relaxation O
period O
was O
prolonged O
45 O
minutes O
after O
each O
form O
of O
stress O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
conclusions O
: O
in O
patients O
with O
co O
##rona X
##ry X
artery O
disease O
, O
do B
##but X
##amine X
induced O
is O
##cha X
##emia X
results O
in O
prolonged O
re O
##versible X
left O
vent O
##ric X
##ular X
d O
##ys X
##function X
, O
presumed O
to O
be O
my O
##oc X
##ard X
##ial X
stunning O
, O
similar O
to O
that O
seen O
after O
exercise O
. O
[SEP] O
[CLS] O
do O
##but X
##amine X
induced O
is O
##cha X
##emia X
could O
therefore O
be O
used O
to O
study O
the O
path O
##op X
##hy X
##sio X
##logy X
of O
this O
phenomenon O
further O
in O
patients O
with O
co O
##rona X
##ry X
artery O
disease O
. O
[SEP] O
[CLS] O
an O
##ore X
##xi X
##gens X
and O
pulmonary O
h O
##yper X
##tens X
##ion X
in O
the O
united O
states O
: O
results O
from O
the O
surveillance O
of O
north O
am O
##eric X
##an X
pulmonary O
h O
##yper X
##tens X
##ion X
. O
[SEP] O
[CLS] O
background O
: O
the O
use O
of O
appetite B
suppress I
##ants X
in O
euro O
##pe X
has O
been O
associated O
with O
the O
development O
of O
primary O
pulmonary O
h O
##yper X
##tens X
##ion X
( O
pp O
##h X
) O
. O
[SEP] O
[CLS] O
recently O
, O
f B
##en X
##f X
##lu X
##ram X
##ine X
appetite I
suppress I
##ants X
became O
widely O
used O
in O
the O
united O
states O
but O
were O
withdrawn O
in O
se O
##pt X
##em X
##ber X
1997 O
because O
of O
concerns O
over O
adverse O
effects O
. O
[SEP] O
[CLS] O
materials O
and O
methods O
: O
we O
conducted O
a O
prospective O
surveillance O
study O
on O
patients O
diagnosed O
with O
pulmonary O
h O
##yper X
##tens X
##ion X
at O
12 O
large O
refer O
##ral X
centers O
in O
north O
am O
##eric X
##a X
. O
[SEP] O
[CLS] O
data O
collected O
on O
patients O
seen O
from O
se O
##pt X
##em X
##ber X
1 O
, O
1996 O
, O
to O
de O
##ce X
##mber X
31 O
, O
1997 O
, O
included O
the O
cause O
of O
the O
pulmonary O
h O
##yper X
##tens X
##ion X
and O
its O
severity O
. O
[SEP] O
[CLS] O
patients O
with O
no O
id O
##ent X
##ifiable X
cause O
of O
pulmonary O
h O
##yper X
##tens X
##ion X
were O
class O
##ed X
as O
pp O
##h X
. O
[SEP] O
[CLS] O
a O
history O
of O
drug O
exposure O
also O
was O
taken O
with O
special O
attention O
on O
the O
use O
of O
anti B
##de X
##press X
##ants X
, O
an O
##ore X
##xi X
##gens X
, O
and O
am B
##phe X
##tamine X
##s X
. O
[SEP] O
[CLS] O
results O
: O
five O
hundred O
seventy O
- O
nine O
patients O
were O
studied O
, O
205 O
with O
pp O
##h X
and O
37 O
##4 X
with O
pulmonary O
h O
##yper X
##tens X
##ion X
from O
other O
causes O
( O
secondary O
pulmonary O
h O
##yper X
##tens X
##ion X
[ O
s O
##ph X
] O
) O
. O
[SEP] O
[CLS] O
the O
use O
of O
an O
##ore X
##xi X
##gens X
was O
common O
in O
both O
groups O
. O
[SEP] O
